Do Hedge Funds and Insiders Love Ligand Pharmaceuticals Inc. (LGND)?

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has experienced a decrease in enthusiasm from smart money lately.

If you’d ask most investors, hedge funds are seen as slow, old financial tools of yesteryear. While there are greater than 8000 funds in operation at the moment, we hone in on the elite of this group, close to 450 funds. It is widely believed that this group has its hands on the majority of the smart money’s total capital, and by paying attention to their best picks, we have discovered a number of investment strategies that have historically outstripped the S&P 500 index. Our small-cap hedge fund strategy outperformed the S&P 500 index by 18 percentage points annually for a decade in our back tests, and since we’ve began to sharing our picks with our subscribers at the end of August 2012, we have topped the S&P 500 index by 24 percentage points in 7 months (check out a sample of our picks).

RENAISSANCE TECHNOLOGIES

Just as important, positive insider trading activity is a second way to break down the world of equities. Just as you’d expect, there are plenty of motivations for a bullish insider to sell shares of his or her company, but just one, very obvious reason why they would initiate a purchase. Various academic studies have demonstrated the useful potential of this method if piggybackers know what to do (learn more here).

Now, we’re going to take a look at the recent action encompassing Ligand Pharmaceuticals Inc. (NASDAQ:LGND).

How have hedgies been trading Ligand Pharmaceuticals Inc. (NASDAQ:LGND)?

In preparation for this year, a total of 5 of the hedge funds we track held long positions in this stock, a change of -29% from the previous quarter. With the smart money’s positions undergoing their usual ebb and flow, there exists a few notable hedge fund managers who were increasing their stakes substantially.

According to our comprehensive database, Baker Bros. Advisors, managed by Julian Baker and Felix Baker, holds the biggest position in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Baker Bros. Advisors has a $1.5 million position in the stock, comprising less than 0.1%% of its 13F portfolio. Coming in second is Thomas Bailard of Bailard Inc, with a $0.9 million position; the fund has 0.2% of its 13F portfolio invested in the stock. Other hedgies that are bullish include Jim Simons’s Renaissance Technologies, D. E. Shaw’s D E Shaw and Cliff Asness’s AQR Capital Management.

Due to the fact that Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has faced declining sentiment from the smart money, logic holds that there lies a certain “tier” of hedgies that decided to sell off their positions entirely heading into 2013. It’s worth mentioning that Richard Schimel’s Diamondback Capital cut the largest position of all the hedgies we monitor, comprising close to $1.4 million in stock.. Gregory Fraser, Rudolph Kluiber, and Timothy Kroch’s fund, GRT Capital Partners, also dropped its stock, about $0.2 million worth. These transactions are interesting, as total hedge fund interest dropped by 2 funds heading into 2013.

Insider trading activity in Ligand Pharmaceuticals Inc. (NASDAQ:LGND)

Insider buying is at its handiest when the company in question has experienced transactions within the past half-year. Over the latest half-year time frame, Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has seen 6 unique insiders purchasing, and 1 insider sales (see the details of insider trades here).

Let’s also take a look at hedge fund and insider activity in other stocks similar to Ligand Pharmaceuticals Inc. (NASDAQ:LGND). These stocks are Akorn, Inc. (NASDAQ:AKRX), Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR), Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), Hi-Tech Pharmacal Co. (NASDAQ:HITK), and Sagent Pharmaceuticals Inc (NASDAQ:SGNT). All of these stocks are in the drugs – generic industry and their market caps match LGND’s market cap.

Company Name # of Hedge Funds # of Insiders Buying # of Insiders Selling
Akorn, Inc. (NASDAQ:AKRX) 10 1 5
Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) 4 1 2
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) 12 0 8
Hi-Tech Pharmacal Co. (NASDAQ:HITK) 11 0 5
Sagent Pharmaceuticals Inc (NASDAQ:SGNT) 11 0 1

With the returns demonstrated by our strategies, everyday investors must always pay attention to hedge fund and insider trading sentiment, and Ligand Pharmaceuticals Inc. (NASDAQ:LGND) shareholders fit into this picture quite nicely.

Click here to learn why you should track hedge funds

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!